Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2

This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020‒2022. The results of our own studies of pharmacological substances based on recombinant IF...

Descripción completa

Detalles Bibliográficos
Autores principales: Oleinik, L. A., Madonov, P. G., Pykhtina, M. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pleiades Publishing 2023
Materias:
Cell Molecular Biology: From DNA Repair to Metabolomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131541/
https://www.ncbi.nlm.nih.gov/pubmed/37128210
http://dx.doi.org/10.1134/S0026893323020152
_version_ 1785031199397249024
author Oleinik, L. A.
Madonov, P. G.
Pykhtina, M. B.
author_facet Oleinik, L. A.
Madonov, P. G.
Pykhtina, M. B.
author_sort Oleinik, L. A.
collection PubMed
description This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020‒2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2.
format Online
Article
Text
id pubmed-10131541
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Pleiades Publishing
record_format MEDLINE/PubMed
spelling pubmed-101315412023-04-27 Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2 Oleinik, L. A. Madonov, P. G. Pykhtina, M. B. Mol Biol Cell Molecular Biology: From DNA Repair to Metabolomics This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020‒2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2. Pleiades Publishing 2023-04-26 2023 /pmc/articles/PMC10131541/ /pubmed/37128210 http://dx.doi.org/10.1134/S0026893323020152 Text en © Pleiades Publishing, Inc. 2023, ISSN 0026-8933, Molecular Biology, 2023, Vol. 57, No. 2, pp. 291–298. © Pleiades Publishing, Inc., 2023.Russian Text © The Author(s), 2023, published in Molekulyarnaya Biologiya, 2023, Vol. 57, No. 2, pp. 307–315. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Cell Molecular Biology: From DNA Repair to Metabolomics
Oleinik, L. A.
Madonov, P. G.
Pykhtina, M. B.
Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
title Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
title_full Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
title_fullStr Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
title_full_unstemmed Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
title_short Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
title_sort potential of interferon lambda as an inhibitor of sars-cov-2
topic Cell Molecular Biology: From DNA Repair to Metabolomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131541/
https://www.ncbi.nlm.nih.gov/pubmed/37128210
http://dx.doi.org/10.1134/S0026893323020152
work_keys_str_mv AT oleinikla potentialofinterferonlambdaasaninhibitorofsarscov2
AT madonovpg potentialofinterferonlambdaasaninhibitorofsarscov2
AT pykhtinamb potentialofinterferonlambdaasaninhibitorofsarscov2

Ejemplares similares